What are the recommended pharmacologic and non‑pharmacologic management strategies for dementia?

Dementia Management

For dementia management, initiate cholinesterase inhibitors (ChEIs) or memantine for Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, or vascular dementia, while simultaneously implementing structured non-pharmacological interventions including cognitive stimulation, physical activity programs, and caregiver support—these non-pharmacological approaches often provide greater clinical impact than medications alone. 1, 2

Pharmacological Management

Cognitive Enhancers

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine are the mainstay pharmacological treatments for:

• Alzheimer's disease (AD)
• Parkinson's disease dementia (PDD)
• Dementia with Lewy bodies (DLB)
• Vascular dementia (VD)

Do NOT prescribe these medications for:

• Frontotemporal dementia
• Mild cognitive impairment (should be deprescribed if already started)
• Other non-specified neurodegenerative conditions 1

When to Discontinue Cognitive Enhancers

Deprescribe ChEIs or memantine if any of the following occur:

• Clinically meaningful cognitive/functional worsening over 6 months despite treatment (excluding delirium or acute medical illness)
• No observable benefit at any point during treatment (no improvement, stabilization, or slowed decline)
• Severe/end-stage dementia with dependence in most basic ADLs
• Intolerable side effects (ChEIs: severe nausea, vomiting, weight loss, falls; Memantine: confusion, dizziness, falls)
• Poor medication adherence preventing safe use 1

Critical exception: Do NOT discontinue ChEIs in patients with active psychotic symptoms, agitation, or aggression until these stabilize—unless the ChEI clearly worsened these symptoms. Continue cognitive enhancers if they have meaningfully reduced neuropsychiatric symptoms, even with cognitive decline 1

Deprescribing Protocol

When discontinuing cognitive enhancers:

1. Reduce dose by 50% every 4 weeks until reaching initial starting dose
2. Continue at starting dose for 4 weeks
3. Then discontinue completely
4. Reinitiate if clinically meaningful worsening occurs after cessation 1

Behavioral and Psychological Symptoms (BPSD)

For aggression and psychosis:

• Risperidone is conditionally recommended (use cautiously given stroke risk and mortality concerns) 3

For agitation in Alzheimer's disease:

• Citalopram is advised as first-line antidepressant 3

For psychosis specifically in Alzheimer's:

• Pimavanserin demonstrated efficacy 3

For REM sleep behavior disorder in Lewy body dementia:

• Cholinesterase inhibitors and memantine show moderate efficacy 3

Non-Pharmacological Management

These interventions often have greater impact than medications and should be implemented concurrently 2, 4:

Core Interventions

• Cognitive stimulation therapy: Structured programs targeting memory and problem-solving
• Physical activity programs: Regular exercise with demonstrated benefits on progression
• Caregiver education and support programs: Reduces caregiver burden and improves patient outcomes
• Environmental modifications: For safety and behavioral management
• Behavioral approaches for agitation: Person-centered strategies before medication 5, 2

Additional Strategies

• Reminiscence therapy
• Reality orientation
• Validation therapy 6

Medical Comorbidity Management

Aggressively manage these conditions as they directly impact cognitive decline:

• Cardiovascular risk factors (hypertension, diabetes, hyperlipidemia)
• Obstructive sleep apnea
• Hearing loss
• Depression and mood disorders
• Pain (often undertreated in dementia)
• Alcohol misuse
• Adverse medication effects (anticholinergics, benzodiazepines)
• Polypharmacy 7, 4

Evidence increasingly shows that consistent cardiovascular risk factor management benefits progression across most dementia types 4

Critical Pitfalls

1. Avoid antipsychotic overuse: Only for severe BPSD unresponsive to non-pharmacological approaches, given stroke and mortality risks
2. Review polypharmacy regularly: Dementia patients are particularly vulnerable to medication adverse effects 6
3. Don't prescribe cognitive enhancers for frontotemporal dementia or MCI 1
4. Address covert medication administration concerns: Ensure ethical and legal compliance 6
5. Monitor for ARIA (amyloid-related imaging abnormalities) if using new anti-amyloid monoclonal antibodies 2

Practical Implementation

Start with this algorithm:

1. Confirm dementia subtype (AD, PDD, DLB, VD vs. other)
2. If AD/PDD/DLB/VD → initiate ChEI or memantine
3. Simultaneously implement non-pharmacological interventions
4. Optimize cardiovascular risk factors and treat comorbidities
5. Reassess at 6 months for meaningful benefit
6. If BPSD emerges → non-pharmacological first, then targeted pharmacotherapy
7. Mobilize interprofessional team and community resources
8. Address advance care planning early 7